首页> 美国卫生研究院文献>other >A Phase 1/2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

【2h】

A Phase 1/2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

机译：费拉尼昔单独或与小剂量地塞米松联用治疗复发/难治性多发性骨髓瘤的1/2期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundFilanesib (ARRY-520) is a highly selective inhibitor of kinesin spindle protein, which has shown preclinical anti-myeloma activity.

机译：背景Filanesib（ARRY-520）是驱动蛋白纺锤体蛋白的高度选择性抑制剂，已显示出临床前的抗骨髓瘤活性。

著录项

期刊名称 other
作者
Jatin J. Shah; Jonathan L. Kaufman; Jeffrey A. Zonder; Adam D. Cohen; William I. Bensinger; Brandi Hilder; Selena Rush; Duncan Walker; Brian Tunquist; Kevin Litwiler; Mieke Ptaszynski; Robert Z. Orlowski; Sagar Lonial;
展开▼
作者单位

展开▼
年(卷),期 -1(123),23
年度 -1
页码 4617–4630
总页数 26
原文格式 PDF
正文语种
中图分类
关键词
Multiple Myeloma Kinesin Spindle Poles Maximum Tolerated Dose Pharmacokinetics Dexamethasone Filanesib;

机译：多发性骨髓瘤;驱动蛋白;纺锤体;最大耐受剂量;药代动力学;地塞米松;Filanesib;

相似文献

外文文献
中文文献
专利

1. A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma [J] . Shah Jatin J., Kaufman Jonathan L., Zonder Jeffrey A., Cancer: A Journal of the American Cancer Society . 2017,第23期

机译：单独的氟纤维和2氟纤维的1和2研究，并与低剂量地塞米松的复发/难以多发性骨髓瘤组合
2. A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma [J] . Ghobrial Irene M., Liu Chia-Jen, Perez Raymond P., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：新型抗CXCR4抗体Ulocuplumab（BMS-936564）的相IB / II研究与Lenalidomide加低剂量地塞米松，或用Bortezomib加上与复发或难倒多发性骨髓瘤的硼替佐米加上地塞米松
3. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma [J] . Hans C. Lee, Jatin J. Shah, Lei Feng, Blood cancer journal. . 2019,第10期

机译：在复发和/或难治性多发性骨髓瘤患者中的氟丝，胭脂蓟马和地塞米松的第1阶段研究
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. A phase 1 study of filanesib carfilzomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma [O] . Hans C. Lee, Jatin J. Shah, Lei Feng, 2019

机译：费拉尼昔卡非佐米和地塞米松在复发和/或难治性多发性骨髓瘤患者中的1期研究
7. Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma [O] . Guillemette Fouquet, Stéphanie Guidez, Valentine Richez, 2018

机译：I50067的I相剂量升级研究，单独的人源化抗CXCR4单克隆抗体，并与Lenalidomide和低剂量地塞米松组合，复发或难治多骨髓瘤

A Phase 1/2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

摘要

著录项

相似文献

相关主题

期刊订阅